Replimune to Present at Two Upcoming Investor Conferences

On October 1, 2024 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported that members from the Replimune management team will present and host investor meetings at the following two conferences (Press release, Replimune, OCT 1, 2024, View Source [SID1234646982]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

BMO 2024 Oncology Summit
Date: Tuesday, October 8, 2024

3rd Annual Roth Healthcare Opportunities Conference
Date: Wednesday, October 9, 2024

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!